Field Medical Secures $40 Million Series A Financing to Advance Pulsed Field Ablation for Ventricular Tachycardia

Apr 23, 2025 17:05 CST Updated 17:06

Field Medical

Developer of Pulsed Electric Field Catheter Ablation Technology

Registration: First Global Orthopedics Conference |Notice for Participants

Registration: First Global Cardiovascular Conference | Heavyweight Highlights

Call for Partners: 2025 Global Surgical Robotics Conference

April 21, 2025Innovative Company in the Field of Pulsed Field Catheter AblationField MedicalAnnounced the successful completion of$40 million (approximately 290 million RMB)The A-round financing. Participants in this round of financing include industry strategic investors, venture capital firms, etc., with several seed round investors reinvesting, highlighting strong confidence in the company's technology.

# Financing Details

This funding will supportComplete two preliminary studies:The VCAS study for ventricular tachycardia (VT) and the Field PULSE study for atrial fibrillation (AF).

At the same time, it will continue to advance the development of Field Medical's commercial pulsed field ablation (PFA) system andExpand the scale of operations to focus on VT for the upcoming activities of the company.Pivotal Trial VERITASGet ready.

Steven Mickelsen, Ph.D., Founder and CEO of Field Medical, stated, "This financing is a crucial step in redefining the approach electrophysiologists take toward ablation therapy.We are accelerating FieldForce^™Development of Ablation Systems, Striving to ExpandThe Scope of Application of the New Generation of Pulsed Field Ablation (PFA) Solutions in the Field of Cardiac Ablation

Field Force is the core product of Field Medical.The first and only PFA system specifically designed for ventricular arrhythmia ablation.This product is suitable for treating persistent monomorphic scar-related ventricular tachycardia (VT), a severe cardiac condition that may lead to sudden cardiac death.

# About FieldForce^™Ablation System

Ventricular arrhythmia is a severe cardiac condition that affects the lives of millions of patients worldwide. Ventricular tachycardia (VT) and premature ventricular contractions (PVC) are two forms of ventricular arrhythmia, which often lead to sudden cardiac death if not properly managed.Since the ventricular wall is much thicker than the atrial wall, ventricular tachycardia ablation often requires creating larger and deeper ablation zones, which traditional thermal ablation finds difficult to achieve.。

FieldForce^™It is an innovative Pulse Field Ablation (PFA) technology that utilizesPressure Contact PFA Catheter Specifically Designed for Ventricles, aiming to provide a safer and more efficient treatment option.。

Technical Features

FieldForce Catheter Tip AdoptedFieldBending Technology, A unique built-in electrode is placed in the fluid lumen shown in the cross-sectional view, generating the desired electric field characteristics by transmitting voltage between the external and internal electrodes.
The tolerance of PFA is a fundamental challenge, as remote stimulation of excitable tissues may cause discomfort and/or involuntary movements, which can interfere with work efficiency. FieldBendingThe catheter's saline flush lumen is equipped with an electrode, has a non-conductive tip at the distal end, and is accompanied by an external electrode.The current flows from a 3-millimeter outer ring located 4 millimeters from the distal tip to the inner electrode.This new bipolar pulse electrode configuration can significantly improve the tolerance of PFA.。
The contact force between the catheter and tissue plays an important role in the efficacy of PFA treatment.Increased contact force can lead to increased lesion depth., and effective lesion formation requires electrode-tissue contact.

FieldForce^™The system utilizes proprietary FieldBending^™Technology,By delivering targeted, transient, high-intensity electric fields through a single-point contact PFA catheter,FieldBending technology can predictably concentrate energy around the catheter, reducing unwanted far-field effects.。This technology allows power to be applied more accurately and concentratedly to the target tissue, enhancing the precision of the treatment.。

In 2022, Field Medical and CardioNXT announced a strategic partnership aimed at delivering a first-of-its-kind pulsed field ablation (PFA) therapy integrated with 3D mapping and navigation.

The two companies plan to develop aIntegrated with PFA, contact force sensing, electromagnetic positioning, and artificial intelligenceMapping FunctionA dedicated system to improve the safety and effectiveness of cardiac catheter ablation procedures while reducing the use of X-rays during surgery.

# First-in-Human Study

Field Medical had already initiated its first-in-human study of the FieldForce pulsed field ablation (PFA) system in May 2024. This study is known as the Ventricular Catheter Ablation Study (VCAS).The VCAS study began at Na Homolce Hospital in Prague, Czech Republic.Recruit at up to 5 locations worldwideUp to 60 patients。

Field Medical Technology: Preoperative and Postoperative Voltage Maps of Full-Thickness Left Ventricular Ablation Lesions Created Solely Through Endocardial Treatment

ResearchAimed to demonstrate the safety and performance of its PFA system through this study, particularlyImprovements on the limitations of existing PFA and radiofrequency (RF) ablation systems, including providing a more time-efficient treatment option for ventricular arrhythmias.。

Preliminary data showsFieldForce has shown great promise in the early stages of the trial.，Has the potential to completely revolutionize complex chambersTraditional catheter ablation for atrial arrhythmias may exceed current standards of care.

December 2024, FieldForce^™The ablation system has been accepted into the FDA's Total Product Life Cycle Advisory Program (TAP) pilot and received the Breakthrough Device Designation.

# Father of PFA

Steven Mickelsen

Dr. Steven Mickelsen is a board-certified clinical cardiac electrophysiologist and an experienced business leader. In the cardiac care industry, he is a pioneer in introducing pulsed field ablation (PFA) technology for patient treatment and is hailed as the "Father of PFA."

Dr. MickelsenFirst established FARAPULSE, Inc., the company is the developer of the first-generation PFA technology.FARAPULSE Finally Acquired by Boston ScientificDr. Mickelsen's work in the PFA field has laid the foundation for the development and clinical application of this technology.

Subsequently,Dr. Mickelsen founded Field Medical, the company focuses onDevelopment of Improved PFA Technology, such as FieldForce catheters and FieldForce generators, and introduced the patented FieldBending technology, which significantlyImproved the efficacy and safety of PFA in treating arrhythmias, especially complex ventricular arrhythmias.。

Dr. Steven Mickelsen said，The company aims to transform ventricular tachycardia ablation into a safe and quick outpatient procedure, with an estimated operation time of just one hour.。